妓院一钑片免看黄大片,亚洲av无码成人精品国产,亚洲AV综合色区无码专区桃色,免费A级毛片在线播放不收费

Epizyme 
Epizyme是位于馬薩諸塞州的劍橋，的一家生物制藥公司，重點(diǎn)是研究治療血液癌??癥和腫瘤。
成立于2007年年底，該公司已匯集了主要的學(xué)術(shù)界和工業(yè)界領(lǐng)袖，從而使令人興奮的發(fā)現(xiàn)，它們從表觀遺傳學(xué)研究中出現(xiàn)，迅速轉(zhuǎn)化成具體方案，而它們將產(chǎn)生重要的是，新穎的，以分子為目標(biāo)的藥物未來。

Epizyme is leading the creation of small molecule histone methyltransferase inhibitors (HMTi), a new class of personalized therapeutics for the treatment of patients with genetically defined cancers, based on breakthroughs in the field of epigenetics. Genetic alterations in HMTs, a family of epigenetic enzymes, drive multiple human diseases. Our approach represents the future of healthcare by matching better medicines with the right patients.

Epizyme's personalized therapeutics are exemplified by our two most advanced therapeutic product programs, targeting the HMTs DOT1L and EZH2.

Epizyme has benchmark partnerships with Celgene, GSK and Eisai and receives funding and strategic support from the Multiple Myeloma Research Foundation (MMRF) and the Leukemia and Lymphoma Society (LLS).

Epizyme was founded in 2007 by Nobel Laureate Professor Robert Horvitz, the David H. Koch Professor of Biology at the Massachusetts Institute of Technology and Professor Yi Zhang of The University of North Carolina Chapel Hill. Using our proprietary product platform, we are creating a product pipeline of novel, potent, and selective small molecule inhibitors (HMTi's) directed to specific enzymes within the 96-member HMT target class. Our experienced management team has collectively been responsible for more than 60 INDs and 7 marketed products and also brings extensive business experience. We have raised $54M to date from leading venture capital firms including Kleiner Perkins Caulfield and Byers, MPM Capital, Bay City Capital, NEA, Astellas Venture Management, and Amgen Ventures. Our partners include Celgene, GSK, Eisai, the Multiple Myeloma Research Foundation, and the Leukemia and Lymphoma Society, and we have realized more than $135M in funding from these partners to date.